Unknown

Dataset Information

0

A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis.


ABSTRACT: Amphotericin B (AmB), the most effective drug against leishmaniasis, has serious toxicity. As Leishmania species are obligate intracellular parasites of antigen presenting cells (APC), an immunopotentiating APC-specific AmB nanocarrier would be ideally suited to reduce the drug dosage and regimen requirements in leishmaniasis treatment. Here, we report a nanocarrier that results in effective treatment shortening of cutaneous leishmaniasis in a mouse model, while also enhancing L. major specific T-cell immune responses in the infected host.We used a Pan-DR-binding epitope (PADRE)-derivatized-dendrimer (PDD), complexed with liposomal amphotericin B (LAmB) in an L. major mouse model and analyzed the therapeutic efficacy of low-dose PDD/LAmB vs full dose LAmB.PDD was shown to escort LAmB to APCs in vivo, enhanced the drug efficacy by 83% and drug APC targeting by 10-fold and significantly reduced parasite burden and toxicity. Fortuitously, the PDD immunopotentiating effect significantly enhanced parasite-specific T-cell responses in immunocompetent infected mice.PDD reduced the effective dose and toxicity of LAmB and resulted in elicitation of strong parasite specific T-cell responses. A reduced effective therapeutic dose was achieved by selective LAmB delivery to APC, bypassing bystander cells, reducing toxicity and inducing antiparasite immunity.

SUBMITTER: Daftarian PM 

PROVIDER: S-EPMC3814840 | biostudies-other | 2013 Dec

REPOSITORIES: biostudies-other

altmetric image

Publications

A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis.

Daftarian Pirouz M PM   Stone Geoffrey W GW   Kovalski Leticia L   Kumar Manoj M   Vosoughi Aram A   Urbieta Maitee M   Blackwelder Pat P   Dikici Emre E   Serafini Paolo P   Duffort Stephanie S   Boodoo Richard R   Rodríguez-Cortés Alhelí A   Lemmon Vance V   Deo Sapna S   Alberola Jordi J   Perez Victor L VL   Daunert Sylvia S   Ager Arba L AL  

The Journal of infectious diseases 20130729 11


<h4>Background</h4>Amphotericin B (AmB), the most effective drug against leishmaniasis, has serious toxicity. As Leishmania species are obligate intracellular parasites of antigen presenting cells (APC), an immunopotentiating APC-specific AmB nanocarrier would be ideally suited to reduce the drug dosage and regimen requirements in leishmaniasis treatment. Here, we report a nanocarrier that results in effective treatment shortening of cutaneous leishmaniasis in a mouse model, while also enhancing  ...[more]

Similar Datasets

| S-EPMC5714383 | biostudies-literature
| S-EPMC6904837 | biostudies-literature
| S-EPMC3518293 | biostudies-other
| S-EPMC6153808 | biostudies-other
| S-EPMC8211079 | biostudies-literature
| S-EPMC6779195 | biostudies-literature
| S-EPMC7924795 | biostudies-literature
| S-EPMC7504813 | biostudies-literature
| S-EPMC8635719 | biostudies-literature
| S-EPMC5571318 | biostudies-literature